What is Scholar Rock Holding Corp (SRRK)?
Scholar Rock Holding Corp is a biopharmaceutical company focused on developing innovative therapies for serious diseases by targeting growth factor biology. The company specializes in the discovery and development of protein therapeutics designed to address unmet medical needs in fibrotic and other serious conditions. Scholar Rock's research efforts include the modulation of transforming growth factor-beta (TGF-β) pathways, which play a critical role in tissue remodeling and fibrosis. The company operates through various stages of drug development, encompassing preclinical research and clinical trials. Its approach integrates advanced protein engineering and molecular biology techniques to create selective inhibitors that aim to improve patient outcomes. Scholar Rock collaborates with academic institutions and industry partners to advance its pipeline and expand its scientific understanding. The company is headquartered in the United States and contributes to the biopharmaceutical sector by focusing on novel mechanisms for disease intervention.
Scholar Rock Holding Corp Stock Price Today: Live Overview
The price today is shaped by trading fluctuations, as Scholar Rock Holding Corp is valued at $44.72. The stock has traded between $43.95 and $47.72, with a daily change percentage of 0%.
FAQ: Scholar Rock Holding Corp (SRRK)
What is the current price of SRRK stock?
The current price stands at $44.72.
Does SRRK pay dividends?
The company does not pay dividends.
Does SRRK have a formal corporate presence or regional headquarters in the UAE?
Scholar Rock Holding Corp operates without an official regional office or subsidiary in the UAE and conducts business through partners and distributors.
What is SRRK best known for?
Scholar Rock Holding Corp is most famous for its development of innovative biopharmaceutical therapies.
What assets are typically shown together with SRRK?
Commonly shown alongside SRRK: Corvus Pharmaceuticals, Inc., Zai Lab Limited, Schwab U.S. Mid-Cap ETF
Latest shares articles



